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between 3 and 18 months after primary bypass grafting
procedures.3 Although a few lesions exhibited evidence of
hypercellularity within the intima, most lesions displayed
areas of hypocellularity with presence of apoptotic cells
and excessive accumulation of extracellular matrix (unpub-
lished data). Apoptosis is a physiologic mechanism of cell
death that regulates normal embryonic development and
remodeling, tissue mass, and cellular homeostasis.4 It has
been implicated in the regulation of intimal thickening in
experimental models of intimal hyperplasia.5 However, the
early profiles of cellular proliferation versus apoptosis after
arterialization of vein grafts have not been characterized.
Our previous observations have also indicated a relatively
greater proliferative activity in smooth muscle cells
(SMCs) of the media and microvascular endothelial cells
of the adventitia.6 Whether neovascularization promotes
the growth of the neointima, as observed in some neo-
plastic processes, or appears secondarily as part of an adap-
tive response to changing metabolic demands remains
unknown.7 To determine the role of cellular proliferation
and apoptosis in neointima formation and the time course
of neovascularization in this process, we expanded the use
of an experimental vein graft in a rodent model.
Human autogenous vein grafts develop myointimal
thickening after transplantation into the arterial circula-
tion.1,2 Vascular stenosis often results from an exaggera-
tion of this hyperplastic process through mechanisms that
remain unknown. Controversy remains about the degree
of proliferative response after angioplasty or after open
revascularization procedures in arteries. An average prolif-
erative index of 1.34% has been shown by means of our
analysis of human vein graft stenotic lesions retrieved
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Purpose: The events preceding myointimal thickening in vein grafts after vascular reconstructions are not well charac-
terized. Indeed, the injury response associated with vein graft arterialization may be different than that observed in the
balloon angioplasty model. Therefore, we used a rat model to study the early cellular response after arterialization of
vein grafts.
Methods: Epigastric veins were placed as femoral artery interposition grafts in 37 male Lewis rats (weight range, 350-
400 g). Vein grafts and contralateral epigastric veins were harvested at different time points (6 hours, 1 day, 2 days, 3
days, 7 days, 14 days, 21 days, 30 days, and 70 days). Tissue specimens were processed for histology and immunohis-
tochemistry with antibodies for the proliferating cell nuclear antigen (PCNA) and for different cell types. Terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay was used as a means of deter-
mining the presence of apoptosis. Electron microscopy was used as means of assessing the integrity of the endothelial
cell surface (SEM) and confirming the presence of apoptosis (TEM). Specimens were also snap frozen in liquid nitro-
gen for RNA isolation and molecular analysis.
Results: At 1 day, endothelial denudation with platelet deposition on the surface was shown by means of SEM. Both
apoptosis and necrosis of smooth muscle cells (SMCs) were present in the media, along with monocyte infiltration.
Cellular proliferation and apoptosis were most intense within the first week of implantation. PCNA staining was first
seen in the adventitial fibroblasts and microvessels, then in the medial SMCs at 3 days. With reverse transcriptase poly-
merase chain reaction, upregulation of vascular endothelial growth factor (VEGF) messenger RNA (mRNA) was noted
at 1 day. Myointimal thickening progressively developed, with no apparent diminution of the luminal area as long as
70 days after implantation. By means of the analysis of the transforming growth factor β1, mRNA showed expression
during intimal thickening and accumulation of extracellular matrix. Reendothelialization was complete at 30 days.
Conclusions: These observations indicate that the cellular composition in our vein graft model is similar to human
stenotic explants. Endothelial denudation is observed in rat vein grafts with complete regeneration by 30 days. VEGF
mRNA is upregulated at 1 day, followed by proliferation of microvessel endothelial cells in the adventitia. Cellular pro-
liferation and apoptosis are minimal after 21 days, with progressive intimal thickening likely to be the result of matrix
accumulation. (J Vasc Surg 2001;33:561-9.)
MATERIALS AND METHODS
The experimental rat vein graft model
Epigastric vein-to-common femoral artery interposi-
tion grafts were placed in 37 inbred male Lewis rats
weighing 350 to 450 g (Fig 1) by the use of a method
similar to that described by Hoch et al.8 In brief, each ani-
mal was anesthetized with an intraperitoneal injection of
pentobarbital sodium (1 mL/kg). An 8-mm segment of
ipsilateral epigastric vein was carefully harvested, gently
irrigated with heparinized saline solution (100 U/mL),
and placed as a reverse interposition graft into a segmen-
tal 3-mm defect of the femoral artery with 6 to 8 inter-
rupted sutures of 10-0 nylon (Ethicon). The entire
procedure was carried out with standard microsurgical
techniques. The total ischemic time was kept to less than
1 hour. Patency was verified by means of an electromag-
netic flow probe connected to a small animal flowmeter
(Transonic Systems). Vein grafts were harvested at 6 hours
(n = 3), 1 day (n = 5), 2 days (n = 5), 3 days (n = 5), 7
days (n = 4), 14 days (n = 4), 21 days (n = 4), 30 days (n
= 4), and 70 days (n = 3). Thrombosed grafts (n = 2) were
discarded. Contralateral epigastric veins were used as con-
trols. Our protocol was approved by the Institutional
Animal Care and Use Committee at the University of
Arizona and was in compliance with federal guidelines
(Guide for the Care and Use of Laboratory Animals,
Institute of Laboratory Animal Resources, Commission
on Life Sciences, National Research Council. Washington:
National Academy Press; 1966).
Histologic analysis
At harvest, specimens were perfusion fixed with either
4% paraformaldehyde or methyl carnoy solution, then
paraffin-embedded. Serial 4-µm sections were stained with
hematoxylin and eosin and Masson trichrome for gross
morphologic examination. Individual microvessels were
identified on light microscopy by means of systematic
scanning of each sample with a 40× objective.
Immunohistochemistry
Tissue sections were incubated with a number of cell
type-specific antibodies against endothelial cells (anti-Factor
VIII-related antigen, Dako), smooth muscle cells (α-
smooth muscle actin, Sigma), and rat macrophages (ED1).
Serial sections at different time points (2 to 3 sections for
each specimen) were stained with a monoclonal antibody
against the proliferating cell nuclear antigen (PCNA) as a
means of assessing cell proliferation. Reactions were per-
formed on an automated immunostainer (Ventana Medical
Systems, Tucson, Ariz).9 Detection of bound antibody was
assessed by means of immunoperoxidase methodologies,
with diaminobenzidine tetrahydrochloride serving as the
color substrate. A PCNA index, in which the number of
PCNA-positive cells was determined as a percentage of the
total number of cells per high-power field times 100, was
calculated.
Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling assay
In situ detection of apoptosis in paraffin-embedded
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Fig 1. Photograph showing the epigastric interposition vein graft in the femoral artery of the Lewis rat vein graft model.
sections was performed by using the terminal deoxynu-
cleotidyl transferase (Tdt)-mediated dUTP-biotin nick
end labeling (TUNEL) method. This technique relies on
the occurrence of internucleosomal DNA fragmentation
by an endonuclease into characteristic 180- to 200-bp
segments. The different steps were performed with the
automated immunohistochemical stainer with the rapid
kinetic mode configuration (Ventana 320ES).9 A TUNEL
index was calculated; the number of TUNEL-positive cells
was determined as a percentage of the total number of
cells per high-power field times 100.
Electron microscopy
Transmission electron microscopy. A separate set of
grafts was used for transmission electron microscopy (TEM),
in which 1- to 2-mm segments were immersed in a mixture
of 4% paraformaldehyde and 1% glutaraldehyde buffered in
0.1 mol/L PO4 (pH, 7.4) and postfixed in 1% osmium
tetroxide. The specimens were subsequently dehydrated in
graded ethanol solutions, then embedded in Epon-Araldite.
Thin sections (60-90 nm) were obtained, placed on copper
grids, and stained with uranyl acetate and lead citrate. They
were examined with a JEOL-100CX II electron microscope
(Japanese Electron Optical Laboratories), and representative
photographs were taken. TEM studies were mainly used as a
means of verifying the presence of apoptosis.
Scanning electron microscopy. For scanning electron
microscopy (SEM), midportions of different specimens
were fixed in 3% glutaraldehyde in 0.1 mol/L phosphate
buffer (pH, 7.4) and postfixed in 1% osmium tetroxide.
They were dehydrated in graded ethanol solutions, critical
point dried from CO2, mounted on specimen stubs, and
sputter-coated with gold-palladium by means of standard
techniques. Specimens were examined in a ISI (Topcon)
WB6 scanning electron microscope (International Scientific
Instruments) to study the surface characteristics.
Total RNA isolation and reverse transcriptase poly-
merase chain reaction
Freshly isolated epigastric vein grafts were immediately
frozen in liquid nitrogen. A minimum of 50 mg of tissue
was homogenized in Trizol (Gibco/BRL), in the manner
described by the manufacturer. After centrifugation, the
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RNA was precipitated with isopropan. Samples were dis-
solved in 15 µL of diethylpyrocarbonate-treated water,
and the concentration was determined at 260 nm. The
integrity of the RNA was determined by means of elec-
trophoresis on a 1% agarose/formaldehyde gel and ethid-
ium bromide staining.
Total RNA was pooled from two individual samples for
analysis. Reverse transcriptase polymerase chain reaction (RT-
PCR) was performed as a means of analyzing expression of vas-
cular endothelial growth factor (VEGF; Genbank Accession
Number AF215725.1), glyceraldehyde 3-P dehydrogenase
(GAPDH; Genbank Accession Number AF106860), and
transforming growth factor beta-1 (TGFβ1; Genbank
Accession Number X52498) with specifically designed oligo-
nucleotide primers (gene Runner, Hastings Software). One
microgram of total RNA was annealed with 1 µg/µL random
hexamer. The product was reversed transcribed into comple-
mentary DNA (cDNA) with Maloney murine leukemia virus
reverse transcriptase (Gibco BRL) at 42°C for 60 minutes.
Then, 50 ng of the cDNA was amplified by means of poly-
merase chain reaction in PCR buffer (10 mmol/L Tris-HCL,
pH = 7.4, 50 mmol/L KCl, 1.5 mmol/L MgCl2, and 0.1%
gelatin), 20 pmol each of the 3´ and 5´ primers, dNTPs, and
Taq DNA polymerase (Fisher Biotech). Samples were dena-
tured at 94°C for 4 minutes, and amplification was carried out
for 30 cycles on a Perkin Elmer-Cetus DNA thermal cycler.
One cycle consisted of 1 minute at 94°C, 2 minutes at 50°C,
and 4 minutes at 72°C. PCR products were analyzed by means
of electrophoresis on 3% agarose gels, stained with ethidium
bromide, and photographed under UV light.
Statistical analysis
PCNA and TUNEL results were expressed as the
mean ± SD. The comparison of PCNA and TUNEL
indices at each time point with that of their respective con-
trols (nonarterialized epigastric veins) was performed by
means of a 2-tailed Student t test with a Bonferroni adjust-
ment. Values less than .006 were considered to be statisti-
cally significant.
RESULTS
General morphologic features. At 1 day and 2 days
after grafting, endothelial denudation with focal platelet
Fig 2. Scanning electron photomicrograph illustrating the surface characteristics of the rat epigastric vein A, before implantation and 
B, 1 day after implantation in the arterial circulation. Note the significant endothelial denudation and platelet deposition (white arrow;
magnification, 4000×).
A B
aggregates present on the surface was shown by means of
SEM (Fig 2, B). Loss of SMCs was noted in the media, as
first evidenced by means of Masson trichrome staining
(Fig 3, B). By means of TEM, many smooth muscle-like
cells were found to display key morphologic features of
apoptosis in the media, including pyknosis and karyor-
rhexis, preservation of structure of cytoplasmic organelles,
cell shrinkage, and presence of apoptotic bodies (Fig 4, A
and B). Apoptotic cells were also present in the adventitia
and in the vessel lumen near the surface. Typical necrotic
cells were also present. Infiltration of mononuclear cells
was noted through the vein graft wall at 1 day. At 7 days,
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Fig 3. Morphologic assessment of arterialized vein graft in the Lewis rat model by means of Masson trichrome stain. A, Normal epi-
gastric vein before implantation (original magnification, 31×). Insert shows a segment of the vein wall at higher magnification (80×). 
B, Arterialized vein graft at 2 days postimplantation. Note significant smooth muscle loss in tunica media (original magnification, 31×).
C, Arterialized vein graft at 7 days after implantation. Note presence of layered nonocclusive recanalized thrombus. There is abundant
microvasculature throughout the vein graft wall (original magnification, 31×). Insert shows microvessels in a segment of the graft wall
(magnification, 40×). D, Arterialized vein graft at 70 days. There is a developed neointima, and the tunica media has well regenerated.
The internal elastic lamina is well delineated (arrowhead). The arrow indicates external elastic lamina (original magnification, 80×). 
L, Lumen; T, thrombus; i, intima; m, media; a, adventitia; mv, microvessels.
Fig 4. Transmission electron micrograph illustrating typical features of apoptosis in a rat vein graft specimen harvested 2 days after
implantation. A, At an earlier stage, there is chromatin condensation, cell shrinkage, and vacuolization of the cytoplasm. B, At a later
stage, apoptotic bodies have been engulfed by a neighboring cell (magnification, 5400×).
A B
microvessels had become abundant in the adventitia and
the media (Fig 3, C). A developing neointima, consisting
predominantly of alpha actin-positive SMCs, was present
at 14 days. Intimal thickening continued to develop, with
no apparent luminal compromise at 70 days (Fig 3, D).
Reendothelialization was complete at 30 days, as evi-
denced by means of SEM.
Profiles of proliferating cell nuclear antigen and ter-
minal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling immunostaining. There was
minimal or no detectable cell replication in control epigas-
tric veins. PCNA-positive cells first appeared in the adventi-
tia of arterialized vein grafts, then in the media. Both
mitogenic and apoptotic activity were most intense during
the first week after implantation (Figs 5 and 6), then
decreased to lower levels (Fig 7). TUNEL-positive cells
were rare in control veins (< 1%). At 1 day, apoptosis
exceeded proliferation; TUNEL- and PCNA-positive cells
became concordant at 7 days and later maintained compa-
rably low levels as long as 30 days after implantation (Fig 7).
At 7 days, similar topographic profiles were also noted;
both PCNA- and TUNEL-positive cells were mainly dis-
persed throughout the media and the adventitia. But at
later points, cellular proliferation, although of lesser
degree, continued to be present in the media and the
adventitia, whereas TUNEL-positive cells were found
mostly in the developing neointima.
Selected growth factors associated with vascular
remodeling and angiogenesis. Early in the course of the
study, our findings of microvascular endothelial cell prolif-
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eration prompted us to study the expression of VEGF, a
potent angiogenic factor,10 by the use of RT-PCR. TGFβ
was also selected because of its described ability to stimu-
late the expansion of extracellular matrix components dur-
ing repair of arterial injury.11 Total RNA was isolated from
the arterialized graft at various time points and analyzed
with oligonucleotide primers designed to amplify the
respective cDNA. Grafts amplified with TGFβ1 oligonu-
cleotide primers produced a 378-bp product12; the gene
appeared to be upregulated approximately 24 hours after
graft implantation and remained elevated until 72 hours
(Fig 8). The same samples amplified with the VEGF
oligonucleotide primers produced a 446-bp product.13 In
contrast to the slow increasing concentration of TGFβ1
mRNA, the VEGF gene was dramatically upregulated at
24 hours and did not diminish significantly until 7 days
after surgery (Fig 8). For comparison, the samples were
amplified with GAPDH, a constitutively active gene, to
ensure the similar levels of the cDNA; Fig 8 shows the
product of 534 bp. These results suggest that the effects
of these growth factors may begin early after the initiation
of the vein arterialization process.
DISCUSSION
Material available on the use of human vein grafts
depends on the occurrence of preocclusive stenotic lesions
leading to surgical graft revision.3 This consideration pre-
cludes the analysis of early pathologic changes associated
with myointimal hyperplasia. The use of an experimental
vein graft model allows analysis of the early injury response
Fig 5. Immunolabeling for the proliferating cell nuclear antigen. Arrows indicate replicating nuclei appearing as dark black (original mag-
nification, 80×). L, Lumen; PCNA, proliferating cell nuclear antigen.
after arterialization. Other investigators, such as Hoch et
al,8 Hirsch and Karnovsky,14 and Faries et al,15 have also
used a rat epigastric vein interposition graft model as a
means of examining various aspects of the development of
intimal hyperplasia. Factors such as mechanical stretch
caused by increased tensile stress after exposure to arterial
blood pressure, vessel wall ischemia, and free radical oxida-
tive injury associated with reperfusion contribute to
endothelial and smooth muscle cell injury.16-21 Inter-
estingly, the amount of SMC loss in the media contrasts
with the limited medial damage observed in the balloon
angioplasty model, even when the angioplasty is per-
formed experimentally in a vein.22 The early injury
response and subsequent cell loss have generally been con-
sidered to consist of necrosis, but our findings confirm
that it may also include apoptosis. This genetically
encoded cell death program has been described in
endothelial cells exposed to hypoxia-reperfusion condi-
tions23 and in animal ischemia-reperfusion models of var-
ious organs.24-26 It has been shown to be an important
mechanism of cellular regulation in a rat balloon-injury
model5 and in a variety of hyperplastic conditions and ath-
erosclerosis.27-30 Clowes et al earlier demonstrated in the
balloon-injured rat carotid artery that replicative activity
of vascular SMCs persisted at relatively high levels (3.8%)
for as long as 3 months after injury. However, the total
arterial SMC content at 2 weeks remained unchanged at
12 months, which suggested that cell death was occur-
ring.29 Hoch and Stark,30 in a preliminary report,
described their findings of apoptosis in rat vein grafts har-
vested at 4 days and at later points. A novelty of our study
was the study of the cellular proliferation in a freshly arte-
rialized vein graft and the comparison of the respective
profiles of cell replication and apoptosis. To our knowl-
edge, similar comparisons had only been performed in a
balloon angioplasty model,31 in which the injury response
appears to differ from the vein adaptation described in
these studies. A quantitative difference in levels of apopto-
sis and proliferation was seen at 1 day after implantation,
with apoptosis greater than proliferation by a ratio of 3 to
1. However, subsequently at 3 days, proliferation indices
exceeded TUNEL indices by a ratio of 2 to 1. At 7 days,
14 days, 21 days, and 30 days, levels of proliferation and
apoptosis were grossly concordant. This apparent mis-
match between proliferation and apoptosis at 3 days may
partly explain a net cellular accumulation early in the
development of intimal hyperplasia. However, fundamen-
tal differences may also account for these results; the
respective duration of these two biological events (prolif-
eration requires 14-18 hours, whereas apoptosis requires 2
hours32), the longer half-life of PCNA positivity,33-34 and
apoptotic cells being quickly engulfed by neighboring
macrophages could certainly lead to an underestimation of
the degree of apoptosis present.
There were also differences noted within each layer of
the vein graft. The apoptotic cells were initially identified
in all three layers of the vein graft, then predominantly in
the neointima at later points. The mitogenic activity began
in the outer layers (adventitia then tunica media) as early
as 1 day after implantation, involved all layers at 7 days,
and then decreased to lower levels. Levels of proliferation
and apoptosis after 21 days were remarkably low (< 1%).
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Fig 6. Detection of apoptosis. Arterialized vein graft at 7 days after implantation showing apoptosis by means of the TUNEL method.
Arrows indicate TUNEL-positive nuclei appearing as dark brown (original magnification, 80×). L, Lumen; TUNEL, transferase-
mediated dUTP-biotin nick end labeling.
These findings also contrast with those described after bal-
loon angioplasty in arteries. In the arterial balloon-injury
model, the development of the neointima has been shown
to result from proliferation and migration of vascular
SMCs from the media to the intima, with half of the SMCs
continuing to proliferate after reaching the intima.35
Moreover, the replicative activity continued at relatively
high levels for as long as 3 months after injury.5 Later in
the development of the neointima, much of the hyper-
plastic response is contributed to by a marked increase in
extracellular matrix from the secretory activity of SMCs
and fibroblasts.36 We observed no apparent diminution of
the luminal area as long as 70 days after implantation, con-
sistent with adequate vascular remodeling without devel-
opment of stenosis. This may represent a limitation of our
animal model to study vein graft stenosis, because no
pathologic remodeling was apparent at 70 days. However,
these observations still bring important implications. In
contrast with a low PCNA index (< 1%) found at 21 days
and at later points in our rat experimental vein graft, an
average PCNA index of 1.34% has been found in human
vein graft stenoses harvested between 6 and 18 months
after implantation, with a peak recorded at 5.2%.3
Combining these two observations, one can speculate that
persistent or renewed cellular replication in arterialized
vein grafts may be among the best biologic predictive
markers of the development of vein graft stenosis.
By means of immunohistochemistry, proliferation of
microvessels was already seen at 2 days. These observa-
tions prompted us to analyze VEGF gene expression, and
upregulation of VEGF mRNA was noted at 24 hours (Fig
8). These data suggest an important role of VEGF as a
direct promoter of angiogenesis in arterialized vein grafts.
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VEGF has been identified as a potent modulator of the
formation of endothelial cell-lined channels.37 Previous
studies have indicated that it is among the factors secreted
by the vessel wall in response to injury38 and also in
hypoxic conditions, providing a physiologic feedback
mechanism to accommodate insufficient tissue oxygena-
tion by promoting blood vessel formation.39 VEGF has
also been implicated in a variety of inflammatory and neo-
plastic conditions.10,38,40,41
TGFβ was also selected for analysis because of its
ability to stimulate extracellular matrix expansion,
because an early accumulation of extracellular matrix was
noted. TGFβ1 mRNA was expressed as early as 6 hours
after vein graft implantation and was upregulated at 
24 hours (Fig 8). Another reason for its selection is 
its known interaction with VEGF. TGFβ1 may con-
tribute to an angiogenic response by stimulating VEGF
production in adventitial fibroblasts.42 However, its role
in angiogenesis remains unclear, because exogenous
TGFβ1 inhibits rat aortic angiogenesis43 and has been
shown to downregulate expression of the VEGF receptor
flk-1 in endothelial cells.44 A more detailed analysis of
VEGF and TGFβ is in progress, and it will characterize
their relationships and their exact role in the develop-
ment of intimal hyperplasia.
In summary, we have shown that early during the
process of vein graft arterialization in a rat model there is
endothelial and smooth muscle cell death by both necro-
sis and apoptosis and infiltration of mononuclear cells in
the vein graft wall. Cellular proliferation begins early in
the adventitia and the tunica media, resulting in increased
microvessel density and SMC regeneration. Neovascular-
ization is an early part of the injury response and con-
Fig 7. Profiles of PCNA and TUNEL indices represented graphically in a 30-day period. Results are expressed as mean ± SD. PCNA
and TUNEL labeling indices (%) are represented on the y axis, and time is indicated on the x axis. *Statistical differences (P < .006)
compared with controls. PCNA, Proliferating cell nuclear antigen; TUNEL, transferase-medicated dUTP-biotin nick end labeling.
tributes to vascular remodeling, rather than being a con-
sequence of neointimal formation that appears later dur-
ing the process. Apoptosis participates in regulation of
cellularity early during the first week, when the mitogenic
response is the most intense. Then, myointimal enlarge-
ment takes place, while cellular proliferation decreases to
low levels (< 1% after 21 days), which implies a relative
increase in the amount of extracellular matrix. The ulti-
mate means of controlling neointimal thickness remains
unknown, but models such as this may provide a useful
experimental system for further investigation.
We thank David Bentley from the Imaging Facility,
Division of Biotechnology, Arizona Research Laboratories,
for his help with transmission electron microscopy, Chris
Wendel for reviewing our statistical analysis, and Rebecca
F. Contreras for her work in immunohistochemistry.
REFERENCES
1. Szilagyi DE, Elliott JP, Hageman JH, Smith RF, Dall’olmo CA. Biologic
fate of autogenous vein implants as arterial substitutes: clinical, angio-
graphic and histopathological observations in femoropopliteal opera-
tions for atherosclerosis. Ann Surg 1973;178:232-46.
2. Bergamini TM, Towne JB, Bandyk DF, Seabrook GR, Schmitt DD.
Experience with in-situ saphenous vein bypasses during 1981 to 1989:
determinant factors of long-term patency. J Vasc Surg 1991;13:137-49.
3. Westerband A, Mills JL, Marek JM, Heimark RL, Hunter GC,
Williams SK. Immunocytochemical determination of cell type and
proliferation rate in human infrainguinal vein graft stenoses. J Vasc
Surg 1997;25:64-73.
4. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and
apoptotic tissues: an overview. Cancer Metastasis Rev 1992;11:95-103.
5. Bochatin-Piallat ML, Gabbiani F, Redard M, Desmouliere A,
Gabbiani G. Apoptosis participates in cellularity regulation during rat
aortic intimal thickening. Am J Pathol 1995;146:1059-64.
6. Westerband A, Mills JL, Hunter GC, Gentile AT, Ihnat D, Heimark
RL. Topography of cell replication in human vein graft stenoses.
Circulation 1998;98:325-30.
7. Westerband A, Gentile AT, Hunter GC, Gooden MA, Aguirre ML,
Berman SS, et al. Intimal growth and neovascularization in human
stenotic vein grafts. J Am Coll Surg 2000;191:264-71.
8. Hoch JR, Stark VK, Hullett DA, Turnipseed WD. Vein graft intimal
hyperplasia: leucocytes and cytokine gene expression. Surgery
1994;116:463-71.
9. Grogan TM, Rangel C, Rimsza L, Bellamy W, Martel R, McDaniel D,
et al. Kinetic-mode, automated double-labeled immunohistochem-
istry and in situ hybridization in diagnostic pathology. In: Weinstein
RS, Graham AR, editors. Advances in pathology and laboratory med-
icine. Vol. 8. St Louis: Mosby-Year Book; 1995. P. 79-100.
10. Ferrara N, Houck K, Jakeman L, Leung D. Molecular and biological
properties of the vascular endothelial growth factor. Endocr Rev
1992;13:18-32. 
11. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA.
Production of transforming growth factor beta 1 during repair of arte-
rial injury. J Clin Invest 1991;88:904-10.
12. Ward MR, Sasahart T, Agrotis A, Dilly RJ, Jennings GL, Bobik A.
Inhibitory effects of tranilast on expression of transforming growth
factor-beta isoforms and receptor in injured arteries. Atherosclerosis
1998;137:267-75.
13. Gang YJ, Libby P. Evidence for apoptosis in advanced human
atheroma: colocalization with interleukin-1-beta-converting enzyme.
Am J Pathol 1995;147:251-66.
14. Hirsch GM, Karnovsky MJ. Inhibition of vein graft intimal prolifera-
tive lesions in the rat by heparin. Am J Pathol 1991;139:581-7.
15. Faries PL, Marin ML, Veith FJ, Ramirez JA, Suggs WD, Parsons RE,
et al. Immunolocalization and temporal distribution of cytokine
expression during the development of vein graft intimal hyperplasia in
an experimental model. J Vasc Surg 1996;24:463-71.
16. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperpla-
sia: association with tangential stress. J Vasc Surg 1987;5:126-36.
17. Brody WR, Kosek JG, Angell WW. Changes in vein grafts following
aorto-coronary bypass induced by pressure and ischemia. J Thorac
Cardiovasc Surg 1972;64:847-54.
18. Ramos JR, Berger K, Mansfield PB, et al. Histologic fate and endothe-
lial changes of distended and non-distended vein grafts. Ann Surg
1976;183:205-28.
19. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, et
al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc
Natl Acad Sci U S A 1995;92:4502-6.
20. Huynh T, Davies M, Trovato M, Svendsen E, Hagen P-O. Alter-
ations in wall tension and shear stress modulate tyrosine kinase sig-
JOURNAL OF VASCULAR SURGERY
568 Westerband et al March 2001
Fig 8. RT-PCR analysis of VEGF and TGFβ1 transcripts in rat vein graft specimens at different time points after arterialization. There is upreg-
ulation of both VEGF and TGFβ1 mRNA at 1 day. No expression is detected in the control vein. GAPDH primers are used for reference.
VEGF, Vascular endothelial growth factor; TGFβ1; transforming growth factor beta-1.
naling and wall remodeling in experimental vein grafts. J Vasc Surg
1999;29:334-44.
21. Dobrin PB. Mechanical factors associated with the development of
intimal and medial thickening in vein grafts subjected to arterial pres-
sure. Hypertension 1995;26:38-43.
22. Davies MG, Dalen H, Svendsen E, Hagen P-O. The functional and
morphological consequences of balloon catheter injury in veins. J
Surg Res 1994;57:122-32.
23. Harrison-Shostak DC, Lemasters JJ, Edgell CJ, et al. Role of ice-like
proteases in endothelial cell hypoxic and reperfusion injury. Biochem
Biophys Res Commun 1997;231:844-7.
24. Chopp M, Li Y. Apoptosis in focal cerebral ischemia. Acta Neurochir
1996;66:21-6.
25. Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces
apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-8.
26. Shah KA, Shurey S, Green CJ. Apoptosis after intestinal ischemia-
reperfusion injury. Transplantation 1997;64:1393-7.
27. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biologic phe-
nomenon with wide-ranging implications in tissue kinetics. Br J
Cancer 1972;26:239-57.
28. Thomas WA, Reiner JM, Florentin FA, Lee KT, Lee WM. Population
dynamics of arterial smooth muscle cells, V: cell proliferation and cell
death during the initial 3 months in atherosclerotic lesions induced in
swine by hypercholesterolemic diet and intimal trauma. Exp Mol
Pathol 1976;24:360-74.
29. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation
after arterial injury, I: smooth muscle cell growth in the absence of
endothelium. Lab Invest 1983;49:327-33.
30. Hoch JR, Stark VK. Apoptosis in vein graft intimal hyperplasia.
Surgical Forum 1997;384-7.
31. Kamenz J, Seibold W, Wohlfrom M, Hanke S, Heise N, Lenz C, et al.
Incidence of intimal proliferation and apoptosis following balloon
angioplasty in an atherosclerotic rabbit model. Cardiovasc Res
2000;45:766-76.
32. Fesus L, Davies PJA, Piacentini M. Apoptosis: molecular mechanisms
in programmed cell death. Eur J Cell Biol 1991;56:170-7.
33. Hall PA, Levison DA, Woods AL, Yu CCW, Kellock BD, Watkins JA,
et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in
paraffin sections: an index of cell proliferation with evidence of dereg-
ulated expression in some neoplasms. J Pathol 1990;162:285-94.
34. Yu CCW, Woods AL, Levison DA. The assessment of cellular prolif-
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 3 Westerband et al 569
eration by immunohistochemistry: a review of currently available
methods and their applications. Histochem J 1992;24:121-31.
35. Snow AD, Bolender RP, Wright TN, et al. Heparin modulates the
composition of extracellular matrix domain surrounding arterial
smooth muscle cells. Am J Pathol 1990;137:313-30.
36. Cox JL, Chaisson DA, Gottlieb AI. Stranger in a strange land: the
pathogenesis of saphenous vein graft stenosis with emphasis on struc-
tural and functional differences between veins and arteries. Prog
Cardiovasc Dis 1991;34:45-68.
37. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, et al.
Therapeutic angiogenesis: a single intraarterial bolus of vascular
endothelial growth factor augments revascularization in a rabbit
ischemic hind limb model. J Clin Invest 1994;93:662-70.
38. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF.
Expression of vascular permeability factor (vascular endothelial
growth factor) by epidermal keratinocytes during wound healing. J
Exp Med 1992;176:1375-9. 
39. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth
factor induced by hypoxia may mediate hypoxia-initiated angiogene-
sis. Nature 1992;359:843-5.
40. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovi ci G, Keshet E.
Upregulation of vascular endothelial growth factor expression
induced by myocardial ischemia: implications for coronary angiogen-
esis. Cardiovasc Res 1994;28:1176-9.
41. Kuzuya M, Satake S, Esaki T, Yamada K, Hayashi T, Naito M, et al.
Induction of angiogenesis by smooth muscle cell-derived factor: pos-
sible role in neovascularization in atherosclerotic plaque. J Cell
Physiol 1995;164:658-67.
42. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela
O, et al. Vascular endothelial growth factor is induced in response to
transforming growth factor-β in fibroblastic and epithelial cells. J Biol
Chem 1994;269:6271-4.
43. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor,
platelet-derived growth factor, and insulin-like growth factor promote
rat aortic angiogenesis in vitro. Am J Pathol 1994;145:1023-9.
44. Mandriota SJ, Menoud PA, Pepper MS. Transforming growth factor
β1 down-regulates vascular endothelial growth factor receptor 2/flk-1
expression in vascular endothelial cells. J Biol Chem 1996;271:
11500-5.
Submitted Jun 13, 2000; accepted Oct 3, 2000.
